Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6192922 | 0.89 | CYP1A2 (0.44) | METAP1CYP1A2ALOX5PPARGPTGES | |
| SCHEMBL28014935 | 0.88 | METAP1 (0.50) | METAP1HPGDSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL28875946 | 0.86 | METAP1 (0.48) | METAP1HPGDSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL28315546 | 0.86 | METAP1 (0.48) | METAP1HPGDSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL28315755 | 0.86 | METAP1 (0.48) | METAP1HPGDSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL28875904 | 0.86 | METAP1 (0.48) | METAP1HPGDSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL28315748 | 0.86 | METAP1 (0.48) | METAP1HPGDSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1734364 | 0.86 | METAP1 (0.47) | METAP1HPGDSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL18281714 | 0.81 | METAP1 (0.42) | METAP1HPGDSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL6987701 | 0.78 | METAP1 (0.46) | METAP1HPGDSLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| EP-1951244-A2 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007062370-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | CALCR, SOST, CALCB | METAP1 1250/4885HPGD 2097/4885SLC1A3 3041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.